Key Takeaways:
A SpaceX filing at the FCC has turned regulatory review of Rocket Lab's $8 billion Iridium takeover into a direct share-price risk through the deal's variable exchange ratio.
Rocket Lab shares fell 6 percent to $63.82 on Friday as SpaceX asked the FCC to scrutinize Iridium Communications' conduct during review of the $8 billion acquisition, with the deal's variable exchange ratio transmitting regulatory friction directly into the stock. The decline extended a bruising stretch for the launch and space systems company, which was down 3 percent year to date through Thursday's close and heading for a third consecutive weekly loss.
"SpaceX does not oppose the transaction, but the Commission should carefully evaluate whether Iridium's conduct is in the public interest," Matthew Turk, satellite policy associate at SpaceX, said in a letter to the FCC. Turk said Iridium had filed more than 50 petitions over eight months seeking to block or restrict rival satellite deployments, describing the company's "well-documented history of anticompetitive attacks against its competitors and American consumers" as a cloud over the proposed transaction.
The dispute centers on SpaceX's next-generation Starlink gateways, which will support gigabit-speed service and share portions of the 19.4-19.6 GHz and 29.1-29.3 GHz spectrum bands with Iridium. Iridium has argued that several proposed ground stations could exceed permissible interference levels "by a wide margin." However, it said coordination talks were underway and that a resolution to the first disputed application seemed close. "Iridium has enjoyed a long and productive relationship with SpaceX," Kara Azocar, regulatory executive at Iridium, wrote in an earlier filing. "Iridium has no interest in impeding SpaceX's business plans."
The September 24 shareholder vote now carries outsized weight. Each Iridium share converts into $27 in cash plus a variable number of Rocket Lab shares based on the 10-day volume-weighted average price near closing, meaning regulatory delay and Rocket Lab share weakness feed each other. Rocket Lab has secured a $3.6 billion bridge facility to fund the transaction, which initially implied an equity value of $6 billion and an enterprise value of $8.1 billion. Former Iridium shareholders are expected to own about 5 percent of the combined company.
The SpaceX filing comes the same week Iridium issued its definitive proxy statement and Rocket Lab its prospectus, formally sending the merger to a shareholder vote on September 24. The variable exchange ratio is the analytical crux for Rocket Lab shareholders: because Iridium holders receive a variable number of Rocket Lab shares set by Rocket Lab's own average price near closing, regulatory delay and share weakness reinforce each other. That mechanic has disrupted merger-arbitrage positioning and explains why regulatory noise transmits directly into Rocket Lab stock rather than staying contained in Iridium.
The selloff extended beyond Rocket Lab. Intuitive Machines fell 5 percent to $15.32, giving back a slice of its 31 percent monthly gain. AST SpaceMobile dropped 6 percent to $58.04, down 15 percent year over year. The Procure Space ETF declined 2 percent to $43.92, while the SPDR S&P 500 ETF Trust slipped 0.3 percent to $768.84, showing the broad market was quiet while the space complex took the hit. No company announcement, filing, contract, or analyst action has been verified at Intuitive Machines or AST SpaceMobile, suggesting both are trading with a space complex that is broadly lower.
Rocket Lab separately reported progress on Neutron, its medium-lift rocket. The reusable Hungry Hippo fairing endured 275,000 pounds of force during qualification testing, with control-surface hubs tested beyond 125 percent of projected flight loads. CEO Peter Beck has cautioned that "the window for an end-of-year launch is narrowing."
Retail sentiment on RKLB improved to neutral from bearish on Stocktwits, with some traders treating the weakness as a buying opportunity. The stock has risen 46 percent over the past year. Analysts at Cantor Fitzgerald raised their price target to $122 from $96 this month, while Roth Capital lowered its target to $110 from $130, both maintaining buy-equivalent ratings. Rocket Lab reported record second-quarter revenue of $234 million, up 62 percent year over year, with backlog growing 137 percent to $2.36 billion.
Investors should keep Rocket Lab exposure sized modestly into the September 24 vote, given how directly regulatory noise now transmits into the stock through the variable exchange ratio. A prolonged or failed deal would hit Rocket Lab's growth strategy, which depends on Iridium's satellite network to expand its space systems business. A successful completion, by contrast, would still face heightened regulatory scrutiny that could shape how the combined company operates its spectrum assets.
This article is for informational purposes only and does not constitute investment advice.
